

Elizabeth A. Keegan

Senior Counsel

E elizabeth.keegan@faberlawgroup.com

P (781) 795 4704



An accomplished transactional lawyer, Elizabeth advises early and mid-stage biotechnology companies engaged in drug development.

Elizabeth helps clients strategically negotiate a variety of agreements, including development and manufacturing agreements, license and collaboration agreements and pre-clinical and clinical services agreements. Elizabeth has deep experience assisting and counseling clients on the various agreements required for the support of global clinical trials and with agreements with academic organizations, including for the transfer of materials, sponsored research and investigator-initiated studies. Elizabeth also supports clients in establishing master agreements for domestic and international clinical trials and services and manufacturing relationships.

BAR ADMISSIONS

California

Massachusetts

EDUCATION

Northeastern University School of Law, J.D.

Colby College, B.A.

Experience

Corporate Associate

Skadden, Arps, Slate, Meagher & Flom

- Representing clients across a wide range of industries with matters pertaining to public and private mergers, stock and asset sales, the registration and sale of equity securities, securities law compliance and corporate governance matters

Legal Intern

Millennium Pharmaceuticals, Inc. (now Takeda Pharmaceutical Company Limited)

Judicial Intern

Massachusetts Superior Court

Client Work

Client Agreements

- Advised a Boston based clinical-stage biotechnology company focused on developing and commercializing precision oncology medicines in the negotiation of a development and manufacturing agreement for the development of capsule formulation and clinical supply with a European CMO
- Representation of a clinical-stage biotech company focused on the development of delivery technologies for cannabinoids in the negotiation of an Investigator-Initiated Research Agreement with a large US academic institution
- Advising Aspa Therapeutics, a subsidiary of BridgeBio Pharma, a biotechnology company focused on developing a treatment for Canavan disease in the negotiation of contract research organization agreements, global clinical trial site agreements and other clinical trial related agreements
- Representation of privately held pharmaceutical company in the negotiation of a Material Transfer Agreement for pre-clinical research with US academic institution
- Research Collaboration Agreement between client and academic institution for client's funding of research regarding CAR T-cell therapy
- Sponsored Research Agreement to explore the activity of client compound on biological samples with specified drug resistance mutations
- Assisted with the negotiation of a Research Collaboration Agreement and Exclusive Patent License Agreement between client and US academic institution for the transfer of intellectual property rights for the development of new therapeutics

Clinical Trials

- Aspa Therapeutics CANaspire, a Phase 1/2 Clinical Trial of BBP-812, an investigational gene therapy for the treatment of Canavan disease
- 4D Molecular Therapeutics Phase 1/2 Trial evaluating 4D-310, a gene replacement therapy for the treatment of Fabry disease and its Phase 1/2 Trial evaluating 4D-125, a gene replacement therapy for X-linked retinitis pigmentosa (XLRP)
- Representation of multiple clients in negotiations of Master Services Agreements with contract research organizations for client clinical trials in North America, Asia, Europe and Australia

Community Involvement

Elizabeth generously donates her time to several philanthropic causes, including Special Olympics, Open Heart Kitchen, Cake4kids, Valley Children's Museum, Tri-Valley Haven and Valley Humane Society.